Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.
Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics against multiple targets. For each project, the agreement grants Sanofi the right to research antibodies and bispecifics generated during the collaboration for potential use as therapeutic products.
Adimab will receive an undisclosed upfront payment, research fees and technical milestones. In addition, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics generated during the collaboration. If Sanofi exercises its option for a particular therapeutic lead, Adimab would receive license fees, clinical milestones and royalties on product sales.
"More and more companies are focused on bispecific approaches to go after intricate disease biology," said Guy Van Meter, vice president of business development at Adimab. "We have made substantial investments to develop our bispecific platform over the past three years. Our capabilities have grown tremendously, and Adimab has added 18 new bispecific therapeutic programs in the past 12 months alone."
